Skip to Main Content

Yet another inspection by the Food and Drug Administration underscores the difficulties that Pfizer (PFE) is having with a key plant that has been responsible for severe shortages of injectables and other drugs.

The problems at the McPherson, Kan., facility, which Pfizer inherited as part of its $16 billion acquisition of Hospira three years ago, include employees who lack training to manufacture, process, or package products; a failure to review unexplained discrepancies in batches of medicines; and inadequate procedures to prevent contamination, according to an agency inspection report last July and August and posted on the FDA web site on Thursday.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!